New Delhi, Dec 13 (IANS) The Supernova Stent -- a new and advanced brain treatment device -- has been demonstrated to be safe and effective for stroke patients, said experts at AIIMS Delhi on Saturday ...

Gemini 3 is Google’s latest AI model, offering improvements in reasoning, coding, and multimodal analysis. New features include the Gemini Agent tool and generative interfaces, such as visual layout ...

First-line ivonescimab plus chemotherapy “may be a new standard of care” for advanced and metastatic squamous non–small cell lung cancer (NSCLC), according to a presentation from HARMONi-6 trial ...

One year ago today, the American people delivered a resounding mandate to President Donald J. Trump when they overwhelmingly re-elected him to an historic second term. In just ten months since his ...

PPARG is a transcription factor that is highly expressed in approximately two-thirds of advanced urothelial cancers and, like many transcription factors, has been historically difficult to drug, Gao ...

As the Long Term Evolution (LTE) of UMTS networks begins its worldwide rollout based on 3rd Generation Partnership Project (3GPP) Release 8, and as new features are considered for Release 9, big ...

Good morning, Nina Lindholm here with the Europe Wire from the London newsroom. We start the week with industrials and manufacturing, where Lincoln International’s Guillaume Suizdak tells me which ...

Foodborne illnesses remain a pressing global health issue, causing millions of infections and economic losses each year. Addressing this challenge requires faster, more accurate, and sustainable ...

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options. A phase 2 study, ATRACTIB (NCT04408118), investigated a ...

The objective response rate was 70.7%, and the median duration of response was 12.2 months. Sacituzumab tirumotecan has demonstrated activity in patients with advanced triple-negative breast cancer ...

Cell and gene therapies in development for unmet needs. The challenge is developing the field with additional CGTs to address a range of diseases with burdensome or ineffective treatment options. Some ...